Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies

被引：36

作者：

Burt, Richard ^{[1
]}

Warcel, Dana ^{[2
]}

Fielding, Adele K. ^{[1
]}

机构：

[1] UCL Canc Inst, 72 Huntley St, London WC1E 6DD, England

[2] UCLH, London, England

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2019年 / 15卷 / 03期

关键词：

blinatumomab; acute lymphoblastic Leukaemia; B-cell non hodgkin Lymphoma; immunotherapeutics; ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; RELAPSE-FREE SURVIVAL; NON-HODGKIN-LYMPHOMA; TERM-FOLLOW-UP; INOTUZUMAB OZOGAMICIN; ADULT PATIENTS; ELDERLY-PATIENTS; SINGLE-ARM; PHASE-II;

D O I：

10.1080/21645515.2018.1540828

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Blinatumomab (Blincyto, Amgen), a bi-specific antibody, is a first-in-class, targeted immunotherapy agent for treatment of B-cell malignancies with a novel mechanism of action which involves in-vivo engagement of the patient's T cells with CD19-expressing tumour cells. Clinical trials have demonstrated its efficacy in relapsed B-cell Acute Lymphoblastic Leukaemia (B-ALL) and B-cell Non-Hodgkin's Lymphoma including in patients who are refractory to chemotherapy. This review summarises the development and design of Blinatumomab, the outcome of clinical studies demonstrating its efficacy and how to manage the administration, practically, including relevant toxicities. We compare and contrast it to other emerging agents for treatment of B-cell malignancies.

引用

页码：594 / 602

页数：9

共 58 条

[1] Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia [J].

Bassan, R. ;

Spinelli, O. ;

Oldani, E. ;

Intermesoli, T. ;

Tosi, M. ;

Peruta, B. ;

Borlenghi, E. ;

Pogliani, E. M. ;

Di Bona, E. ;

Cassibba, V. ;

Scattolin, A. M. ;

Romani, C. ;

Ciceri, F. ;

Cortelezzi, A. ;

Gianfaldoni, G. ;

Mattei, D. ;

Audisio, E. ;

Rambaldi, A. .

BLOOD CANCER JOURNAL, 2014, 4 :e225-e225

[2] Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia AMeta-analysis [J].

Berry, Donald A. ;

Zhou, Shouhao ;

Higley, Howard ;

Mukundan, Lata ;

Fu, Shuangshuang ;

Reaman, Gregory H. ;

Wood, Brent L. ;

Kelloff, Gary J. ;

Jessup, J. Milburn ;

Radich, Jerald P. .

JAMA ONCOLOGY, 2017, 3 (07)

[3] Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia [J].

Brüggemann, M ;

Raff, T ;

Flohr, T ;

Gökbuget, N ;

Nakao, M ;

Droese, J ;

Lüschen, S ;

Pott, C ;

Ritgen, M ;

Scheuring, U ;

Horst, HA ;

Thiel, E ;

Hoelzer, D ;

Bartram, CR ;

Kneba, M .

BLOOD, 2006, 107 (03) :1116-1123

[4] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[5] Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [J].

Davids, Matthew S. ;

Roberts, Andrew W. ;

Seymour, John F. ;

Pagel, John M. ;

Kahl, Brad S. ;

Wierda, William G. ;

Puvvada, Soham ;

Kipps, Thomas J. ;

Anderson, Mary Ann ;

Salem, Ahmed Hamed ;

Dunbar, Martin ;

Zhu, Ming ;

Peale, Franklin ;

Ross, Jeremy A. ;

Gressick, Lori ;

Desai, Monali ;

Kim, Su Young ;

Verdugo, Maria ;

Humerickhouse, Rod A. ;

Gordon, Gary B. ;

Gerecitano, John F. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08) :826-833

[6] Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase 1b dose-finding study [J].

de Vos, S. ;

Swinnen, L. J. ;

Wang, D. ;

Reid, E. ;

Fowler, N. ;

Cordero, J. ;

Dunbar, M. ;

Enschede, S. H. ;

Nolan, C. ;

Petrich, A. M. ;

Ross, J. A. ;

Salem, A. H. ;

Verdugo, M. ;

Agarwal, S. ;

Zhou, L. ;

Kozloff, M. ;

Nastoupil, L. J. ;

Flowers, C. R. .

ANNALS OF ONCOLOGY, 2018, 29 (09) :1932-1938

[7]

Dreyling M, 2017, ANN ONCOL, V28, P62, DOI [10.1093/annonc/mdx223, 10.1093/annonc/mdx289]

[8] Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry [J].

Farahat, N ;

Morilla, A ;

Owusu-Ankomah, K ;

Morilla, R ;

Pinkerton, CR ;

Treleaven, JG ;

Matutes, E ;

Powles, RL ;

Catovsky, D .

BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (01) :158-164

[9] Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study [J].

Fielding, Adele K. ;

Richards, Susan M. ;

Chopra, Rajesh ;

Lazarus, Hillard M. ;

Litzow, Mark R. ;

Buck, Georgina ;

Durrant, I. Jill ;

Luger, Selina M. ;

Marks, David I. ;

Franklin, Ian M. ;

McMillan, Andrew K. ;

Tallman, Martin S. ;

Rowe, Jacob M. ;

Goldstone, Anthony H. .

BLOOD, 2007, 109 (03) :944-950

[10] Current Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia [J].

Fielding, Adele K. .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 25 (06) :1255-+

← 1 2 3 4 5 6 →